Epizyme Inc (NASDAQ: EPZM) has priced its underwritten public offering of 56.7 million shares at .50 per share for gross proceeds of million.

  • The offer price represents a discount of almost 21% from the last close price of $1.90 on Wednesday.

  • Underwriters have an option to purchase up to an additional 8.5 million shares.

  • Epizyme will use the proceeds to fund the global development & commercialization of tazemetostat, Phase 1/1b trial of EZM0414, the discovery & identification of additional product candidates, and fund initiatives to accelerate commercial adoption of TAZVERIK.

  • Earlier this month, the Company posted preliminary Tazverik (tazemetostat) sales of .2 million – 11.7 million in Q4 FY21 and $30.6 million – 31.1 million in FY21.

  • The offering is expected to close by January 31.

  • Price Action: EPZM shares are down 30.5% at $1.32 during the premarket session on the last check Thursday.

See more from Benzinga

  • Zymeworks Raises 0M Via Equity Issued At 14% Discount

  • Conmed Posts Mixed Bag Q4 Earnings, Issues FY22 Outlook

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888